Working together to treat rare disease
Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.
Board of Directors
Khandan Baradaran, PhD
Scott Dorfman, BBA
Cofounder & Board Chairman
Brian Fenton
President & CEO, Photys Therapeutics
Elizabeth Attias, Sc.D.
CEO & President, Atom Strategic Consulting
Chief Strategy and Development Officer, Sermonix Pharmaceuticals
Mat Pletcher, PhD
CSO, Weaver Biosciences
Founder, RDH12 Fund for Sight
Gregory Robinson, PhD
Joy Cavagnaro, PhD
President, Access Bio
Advisors
Tiansen Li, PhD
Senior Investigator, Retinal Cell Biology and Degeneration Section, NEI
Luk Vandenberghe, PhD
Cofounder, Odylia Therapeutics
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Jean Bennett, MD, PhD
Professor, Perelman School of Medicine
University of Pennsylvania
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Alan Spiro, BA, PhD, JD
Partner, ExSight Ventures
Founders
Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear
Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear
Scott Dorfman, BBA
CEO, Odylia Therapeutics
John Fernandez, MS
President and CEO,
Massachusetts Eye and Ear
Joan Miller, MD
Chief of Ophthalmology,
Massachusetts Eye and Ear